Business Wire

Murata Announces Production of "CELLNETTA" – the World's First Metal Cell Fractionation Filter

Share

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announced today that has successfully commercialized and mass produced "CELLNETTA," the world’s first*1 metal cell fractionation filter designed for the rapid and precise selection and recovery of target cells from cell suspensions*2 used in regenerative medicine and cell pharmaceutical research and development. Target applications include fractionation (selection and recovery), concentration, and filtration in research and development for regenerative medicine technologies or cellular pharmaceuticals, as well as biotechnology across agriculture, forestry, food, and energy industries. The product will be showcased at the 24th Annual Meeting of the Japanese Society for Regenerative Medicine happening March 20-22, 2025 at Pacifico Yokohama North.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312846176/en/

[Murata Manufacturing Co., Ltd.] "CELLNETTA" –the metal cell fractionation filter

*1 According to our research (as of March 16, 2025)

In recent years, regenerative medicine and cell therapy have gained worldwide recognition for their potential to treat previously incurable diseases by restoring lost cells or bodily functions. However, these advancements face significant challenges, including the substantial costs and time required for research and development. To accelerate the delivery of effective medical technologies and pharmaceuticals to clinical settings, innovative methods that can streamline the R&D process are urgently needed.

In developing this product, the Company focused on the process of selecting and recovering target cells from cell suspensions – a critical step in research related to regenerative medicine and cell therapy. The CELLNETTA solution features microscale pores arranged in a mesh structure on a thin metallic film, created using advanced thin-film microfabrication technology honed over years of electronic component manufacturing. By precisely controlling the pore sizes on the thin metal film, which minimizes cell adhesion, this filter enables efficient selection and recovery of target cells without leaving residues.

Historically, selecting and recovering target cells required skilled personnel and equipment, such as centrifuges*3, or the use of membrane filters made from fibers or resins. CELLNETTA simplifies this process by eliminating the need for specialized skills and bulky devices, enabling quicker selection and recovery of target cells compared to fiber- or resin-based filters. This innovative method not only streamlines tasks that were once considered challenging with conventional techniques but also offers high-precision fractionation. Key features include:

  • Rapid Separation of Target Cells
    The filter's large open area enables efficient separation of target cells from liquid media without the need for pumps; simply pouring the cell suspension is sufficient.

Case Study 1: Time taken to pass 50 ml of Phosphate-Buffered Saline (PBS) through a membrane filter with a pore size of 5 µm compared to CELLNETTA.
Membrane Filter: Approx. 5 minutes
CELLNETTA: Approx. 20 seconds
Note: Since the membrane filter relies on applied pressure for fluid passage, it is not feasible to measure the flow times under identical conditions.

Case Study 2: Time required to process a 10 ml cell suspension of HL-60 cells at a concentration of 1×105 cells/ml using a centrifuge versus CELLNETTA.
Centrifuge: Approx. 5 to 15 minutes
CELLNETTA: Approx. 50 seconds

  • High Precision in Cell Fractionation
    Featuring uniform micrometer-scale pores, the filter allows for precise fractionation tailored to target cell sizes by selecting the appropriate mesh size.
  • Considerations for Biocompatibility and Hygiene
    The filter is made from biocompatible metal materials designed to minimize any impact on processed cells. Each product is individually packaged and sterilized using gamma-ray irradiation.
  • Wide Range of Product Options
    The filter is offered in six mesh sizes (5µm, 10µm, 15µm, 20µm, 100µm, 200µm), making it adaptable for a wide range of target cells and suitable for various applications.

Murata is dedicated to fostering innovation across various sectors, including healthcare, while providing solutions that address pressing social challenges. For more details, please visit here. For inquiries regarding CELLNETTA, click here.

*CELLNETTA is not intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or any other medical condition. CELLNETTA is not designed, manufactured, or marketed as a medical device as defined by applicable laws and regulations.
*2 A cell suspension refers to a fluid that has cells or microorganisms suspended (floating or dispersed) in a liquid medium during culture. In research and technology development related to regenerative medicine, biotechnology, and cell biology, cell suspensions are managed throughout various processes such as tissue collection, cell purification, culture, passaging/splitting, administration, pre-surgical preparation, concentration, and quality inspection while selecting and recovering target cells.
*3 Centrifugation: A method that utilizes differences in density to separate and recover target cells through centrifugal force.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250312846176/en/

Contacts

For more information, please contact:
Murata Manufacturing Co., Ltd.
Tatsuki Ichioka
prsec_mmc@murata.com
Corporate Communications Department

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Energy Vault Acquires 1.0 GWh Stoney Creek BESS from Enervest, Advancing Project Development under the LTESA Award from New South Wales17.3.2025 15:15:00 EET | Press release

Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a leader in sustainable, grid-scale energy storage solutions, today announced that it has executed an agreement to acquire the 125 MW / 1,000 MWh Stoney Creek Battery Energy Storage System (BESS) from Enervest Group, a leading Australian project developer. Energy Vault and Enervest are progressing through development activities, market integration, and procurement for the project as it prepares for site mobilization and pre-construction activities later this year. The acquisition of the Stoney Creek BESS with a construction value of USD $220 million (AUD $350 million), is aligned with Energy Vault’s growing portfolio of ‘Owned & Operated’ projects, demonstrating continued successful execution of the global growth strategy outlined during the Company’s May 2024 Investor and Analyst Day. As recently announced, the Stoney Creek BESS has been awarded a 14 year Long-Term Energy Service Agreement (LTESA) by the Australian Energy Mark

Futur Publishes Annual and Sustainability Report for 202417.3.2025 15:03:00 EET | Press release

Today, Futur Pension AB (publ) publishes its Annual and Sustainability Report for 2024. Read it at www.futur.se/financial-information We are pleased to note that Futur’s customers overall have experienced strong returns in 2024. In particular, customers with exposure to global equities, led by the U.S. market, have seen significant growth of their capital. Thereto, we are proud of high inflows of new savings and pension capital. In line with last years, Futur has continued to invest heavily in its technology platform to ensure a high level of service and cost efficiency. “For the coming years, we see great opportunities to continue growing by developing innovative and efficient services for savings and pension together with our partners. In 2025, we will continue our investments in digital self-service solutions to strengthen our position as the obvious choice for savings and pensions. We also look forward to more and deeper collaborations throughout the year,” says Torgny Johansson, C

PUMA Becomes Official Partner of the Premier League17.3.2025 13:42:00 EET | Press release

Global sports company PUMA has signed an official agreement with the Premier League, the most-watched football league globally, as part of the company’s strategy to elevate the brand and strengthen its sports performance credibility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317329567/en/ Global sports company PUMA has signed an official agreement with the Premier League, the most-watched football league globally, as part of the company’s strategy to elevate the brand and strengthen its sports performance credibility. This landmark collaboration will see PUMA become the Official Ball Supplier of the Premier League, which includes the provision of match balls at all League matches from the start of the 2025/26 season. Through this partnership, PUMA will also support the Premier League across multiple initiatives, from community-based football programs that nurture grassroots talent to high-impact marketing campaigns a

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa17.3.2025 13:00:00 EET | Press release

Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg). A significantly higher proportion of patients treated with povorcitinib once daily (QD) versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count. The percentage of povorcitinib treated patients achieving HiSCR50 compared to placebo at Week 12 was: STOP-HS1: 45 mg: 40.2% vs. 29.7% [P=0.024] 75 mg: 40.6% vs 29.7% [P=0.022] STOP-HS2: 45 mg: 42.3% vs. 28.6% [P=0.004] 75 mg: 42.3% vs. 28.6% [P=0.003] Within

Adara Ventures Announces First Close of €100M AV4 Fund, Targeting Cybersecurity, AI & Digital Infrastructure17.3.2025 12:03:00 EET | Press release

Adara Ventures, the European venture capital firm specialising in early-stage deep tech investments, today announced the first close of its fourth flagship fund, AV4, targeting €100 million in capital commitments. This new fund reinforces Adara’s commitment to delivering strong returns in strategic sectors, including cybersecurity, applied AI, digital infrastructure, hardware components, digital health, and space. “We are immensely proud to announce the successful first close of AV4,” said Nico Goulet, Founding Partner of Adara Ventures. “Over the past nine months, we have secured in excess of €140 million in commitments across our fourth-generation funds. Alongside AV4, this includes Adara Ventures Energy (AVE), our first Pan-European fund dedicated to energy transition technologies. In one of the most challenging fundraising environments of the past 20 years, our strong DPI record, disciplined investment strategy, and focused fund model make AV4 a compelling opportunity for our limit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye